Genetic and clinical characteristics of treatment-resistant depression using primary care records in two UK cohorts.
Journal
Molecular psychiatry
ISSN: 1476-5578
Titre abrégé: Mol Psychiatry
Pays: England
ID NLM: 9607835
Informations de publication
Date de publication:
07 2021
07 2021
Historique:
received:
26
10
2020
accepted:
24
02
2021
revised:
12
02
2021
pubmed:
24
3
2021
medline:
27
1
2022
entrez:
23
3
2021
Statut:
ppublish
Résumé
Treatment-resistant depression (TRD) is a major contributor to the disability caused by major depressive disorder (MDD). Primary care electronic health records provide an easily accessible approach to investigate TRD clinical and genetic characteristics. MDD defined from primary care records in UK Biobank (UKB) and EXCEED studies was compared with other measures of depression and tested for association with MDD polygenic risk score (PRS). Using prescribing records, TRD was defined from at least two switches between antidepressant drugs, each prescribed for at least 6 weeks. Clinical-demographic characteristics, SNP-based heritability (h
Identifiants
pubmed: 33753889
doi: 10.1038/s41380-021-01062-9
pii: 10.1038/s41380-021-01062-9
pmc: PMC8505242
doi:
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
3363-3373Subventions
Organisme : Medical Research Council
ID : MR/P00167X/1
Pays : United Kingdom
Organisme : Medical Research Council
ID : MR/N015746
Pays : United Kingdom
Organisme : Department of Health
Pays : United Kingdom
Organisme : Medical Research Council
ID : MR/S015132/1
Pays : United Kingdom
Organisme : Medical Research Council
ID : MC_QA137853
Pays : United Kingdom
Organisme : Medical Research Council
ID : MC_PC_17228
Pays : United Kingdom
Organisme : Medical Research Council
ID : MR/S0151132
Pays : United Kingdom
Informations de copyright
© 2021. The Author(s).
Références
GBD 2015 Disease and Injury Incidence and Prevalence Collaborators. Global, regional, and national incidence, prevalence, and years lived with disability for 310 diseases and injuries, 1990-2015: a systematic analysis for the Global Burden of Disease Study 2015. Lancet Lond Engl. 2016;388:1545–602. 08
doi: 10.1016/S0140-6736(16)31678-6
Gaynes BN, Warden D, Trivedi MH, Wisniewski SR, Fava M, Rush AJ. What did STAR*D teach us? Results from a large-scale, practical, clinical trial for patients with depression. Psychiatr Serv Wash DC. 2009;60:1439–45.
doi: 10.1176/ps.2009.60.11.1439
Rizvi SJ, Grima E, Tan M, Rotzinger S, Lin P, McIntyre RS, et al. Treatment-resistant depression in primary care across Canada. Can J Psychiatry. 2014;59:349–57. 1
pubmed: 25007419
pmcid: 4086317
doi: 10.1177/070674371405900702
Cipriani A, Furukawa TA, Salanti G, Chaimani A, Atkinson LZ, Ogawa Y, et al. Comparative efficacy and acceptability of 21 antidepressant drugs for the acute treatment of adults with major depressive disorder: a systematic review and network meta-analysis. Lancet Lond Engl. 2018;391:1357–66. 07
doi: 10.1016/S0140-6736(17)32802-7
Ferenchick EK, Ramanuj P, Pincus HA. Depression in primary care: part 1—screening and diagnosis. BMJ. 2019;365:l794.
Wigmore EM, Hafferty JD, Hall LS, Howard DM, Clarke T-K, Fabbri C, et al. Genome-wide association study of antidepressant treatment resistance in a population-based cohort using health service prescription data and meta-analysis with GENDEP. Pharmacogenomics J. 2020;20:329–41.
pubmed: 30700811
doi: 10.1038/s41397-019-0067-3
Trivedi MH, Rush AJ, Wisniewski SR, Nierenberg AA, Warden D, Ritz L, et al. Evaluation of outcomes with citalopram for depression using measurement-based care in STAR*D: implications for clinical practice. Am J Psychiatry. 2006;163:28–40.
pubmed: 16390886
doi: 10.1176/appi.ajp.163.1.28
Li G, Fife D, Wang G, Sheehan JJ, Bodén R, Brandt L, et al. All-cause mortality in patients with treatment-resistant depression: a cohort study in the US population. Ann Gen Psychiatry. 2019;18:23.
pubmed: 31583010
pmcid: 6771113
doi: 10.1186/s12991-019-0248-0
McAllister-Williams RH, Arango C, Blier P, Demyttenaere K, Falkai P, Gorwood P, et al. The identification, assessment and management of difficult-to-treat depression: an international consensus statement. J Affect Disord. 2020;267:264–82.
pubmed: 32217227
doi: 10.1016/j.jad.2020.02.023
Li QS, Tian C, Seabrook GR, Drevets WC, Narayan VA. Analysis of 23andMe antidepressant efficacy survey data: implication of circadian rhythm and neuroplasticity in bupropion response. Transl Psychiatry. 2016;6:e889. 13
pubmed: 27622933
pmcid: 5048209
doi: 10.1038/tp.2016.171
Fabbri C, Kasper S, Kautzky A, Bartova L, Dold M, Zohar J, et al. Genome-wide association study of treatment-resistance in depression and meta-analysis of three independent samples. Br J Psychiatry. 2019;214:36–41.
pubmed: 30468137
doi: 10.1192/bjp.2018.256
23andMe Research Team, Li QS, Tian C, Hinds D. Genome-wide association studies of antidepressant class response and treatment-resistant depression. Transl Psychiatry. 2020;10:360.
Pain O, Hodgson K, Trubetskoy V, Ripke S, Marshe V, Adams M, et al. Antidepressant response in major depressive disorder: a genome-wide association study. medRxiv [Internet]. 2020 Dec 15; Available from: https://www.medrxiv.org/content/10.1101/2020.12.11.20245035v1.full.pdf+html
Smoller JW. The use of electronic health records for psychiatric phenotyping and genomics. Am J Med Genet Part B Neuropsychiatr Genet. 2018;177:601–12.
doi: 10.1002/ajmg.b.32548
Davies MR, Kalsi G, Armour C, Jones IR, McIntosh AM, Smith DJ, et al. The genetic links to anxiety and depression (GLAD) study: online recruitment into the largest recontactable study of depression and anxiety. Behav Res Ther. 2019;123:103503.
pubmed: 31715324
pmcid: 6891252
doi: 10.1016/j.brat.2019.103503
Wray NR, Ripke S, Mattheisen M, Trzaskowski M, Byrne EM, Abdellaoui A, et al. Genome-wide association analyses identify 44 risk variants and refine the genetic architecture of major depression. Nat Genet. 2018;50:668–81.
pubmed: 29700475
pmcid: 5934326
doi: 10.1038/s41588-018-0090-3
John C, Reeve NF, Free RC, Williams AT, Ntalla I, Farmaki A-E, et al. Cohort profile: extended cohort for E-health, environment and DNA (EXCEED). Int J Epidemiol. 2019;48:678–679j. 01
pubmed: 31062032
pmcid: 6659362
doi: 10.1093/ije/dyz073
UK Biobank. Primary Care Linked Data [Internet]. 2019. Available from: http://biobank.ndph.ox.ac.uk/showcase/showcase/docs/primary_care_data.pdf
UK Biobank. UK Biobank Protocol [Internet]. 2011. Available from: https://www.ukbiobank.ac.uk/wp-content/uploads/2011/11/UK-Biobank-Protocol.pdf
Davis LL, Wisniewski SR, Howland RH, Trivedi MH, Husain MM, Fava M, et al. Does comorbid substance use disorder impair recovery from major depression with SSRI treatment? An analysis of the STAR*D level one treatment outcomes. Drug Alcohol Depend. 2010;107:161–70. 1
pubmed: 19945804
doi: 10.1016/j.drugalcdep.2009.10.003
Davis LL, Pilkinton P, Wisniewski SR, Trivedi MH, Gaynes BN, Howland RH, et al. Effect of concurrent substance use disorder on the effectiveness of single and combination antidepressant medications for the treatment of major depression: an exploratory analysis of a single-blind randomized trial. Depress Anxiety. 2012;29:111–22.
pubmed: 22495941
pmcid: 3325509
doi: 10.1002/da.20918
Mao Y-M, Zhang M-D. Augmentation with antidepressants in schizophrenia treatment: benefit or risk. Neuropsychiatr Dis Treat. 2015;11:701–13. 16
pubmed: 25834445
pmcid: 4370910
Davis KAS, Coleman JRI, Adams M, Allen N, Breen G, Cullen B, et al. Mental health in UK Biobank - development, implementation and results from an online questionnaire completed by 157 366 participants: a reanalysis. BJPsych Open. 2020;6:e18. 6
pubmed: 32026800
pmcid: 7176892
doi: 10.1192/bjo.2019.100
Smith DJ, Nicholl BI, Cullen B, Martin D, Ul-Haq Z, Evans J, et al. Prevalence and characteristics of probable major depression and bipolar disorder within UK biobank: cross-sectional study of 172,751 participants. PloS One. 2013;8:e75362.
pubmed: 24282498
pmcid: 3839907
doi: 10.1371/journal.pone.0075362
Taylor D, Barnes TRE, Young AH. The Maudsley prescribing guidelines in psychiatry. 13th Edition. Wiley-Blackwell, Chichester, West Sussex; 2018.
Choi SW, O’Reilly PF. PRSice-2: Polygenic risk score software for biobank-scale data. GigaScience. 2019;8:giz082.
Lee SH, Goddard ME, Wray NR, Visscher PM. A better coefficient of determination for genetic profile analysis: a better coefficient of determination. Genet Epidemiol. 2012;36:214–24.
pubmed: 22714935
doi: 10.1002/gepi.21614
Lim GY, Tam WW, Lu Y, Ho CS, Zhang MW, Ho RC. Prevalence of depression in the community from 30 countries between 1994 and 2014. Sci Rep. 2018;8:2861. 12
pubmed: 29434331
pmcid: 5809481
doi: 10.1038/s41598-018-21243-x
Yang J, Lee SH, Goddard ME, Visscher PM. GCTA: a tool for genome-wide complex trait analysis. Am J Hum Genet. 2011;88:76–82. 7
pubmed: 21167468
pmcid: 3014363
doi: 10.1016/j.ajhg.2010.11.011
Zeng J, de Vlaming R, Wu Y, Robinson MR, Lloyd-Jones LR, Yengo L, et al. Signatures of negative selection in the genetic architecture of human complex traits. Nat Genet. 2018;50:746–53.
pubmed: 29662166
doi: 10.1038/s41588-018-0101-4
Zheng J, Erzurumluoglu AM, Elsworth BL, Kemp JP, Howe L, Haycock PC, et al. LD Hub: a centralized database and web interface to perform LD score regression that maximizes the potential of summary level GWAS data for SNP heritability and genetic correlation analysis. Bioinformatics 2017;33:272–9. 15
pubmed: 27663502
doi: 10.1093/bioinformatics/btw613
Yap CX, Sidorenko J, Marioni RE, Yengo L, Wray NR, Visscher PM. Misestimation of heritability and prediction accuracy of male-pattern baldness. Nat Commun. 2018;9:2537.
Bycroft C, Freeman C, Petkova D, Band G, Elliott LT, Sharp K, et al. The UK Biobank resource with deep phenotyping and genomic data. Nature 2018;562:203–9.
pubmed: 30305743
pmcid: 6786975
doi: 10.1038/s41586-018-0579-z
Pardiñas AF, Holmans P, Pocklington AJ, Escott-Price V, Ripke S, Carrera N, et al. Common schizophrenia alleles are enriched in mutation-intolerant genes and in regions under strong background selection. Nat Genet. 2018;50:381–9.
pubmed: 29483656
pmcid: 5918692
doi: 10.1038/s41588-018-0059-2
Stahl EA, Breen G, Forstner AJ, McQuillin A, Ripke S, Trubetskoy V, et al. Genome-wide association study identifies 30 loci associated with bipolar disorder. Nat Genet. 2019;51:793–803.
pubmed: 31043756
pmcid: 6956732
doi: 10.1038/s41588-019-0397-8
Demontis D, Walters RK, Martin J, Mattheisen M, Als TD, Agerbo E, et al. Discovery of the first genome-wide significant risk loci for attention deficit/hyperactivity disorder. Nat Genet. 2019;51:63–75.
pubmed: 30478444
doi: 10.1038/s41588-018-0269-7
Okbay A, Baselmans BML, De Neve J-E, Turley P, Nivard MG, Fontana MA, et al. Genetic variants associated with subjective well-being, depressive symptoms, and neuroticism identified through genome-wide analyses. Nat Genet. 2016;48:624–33.
pubmed: 27089181
pmcid: 4884152
doi: 10.1038/ng.3552
Benyamin B, Pourcain B, Davis OS, Davies G, Hansell NK, Brion M-JA, et al. Childhood intelligence is heritable, highly polygenic and associated with FNBP1L. Mol Psychiatry. 2014;19:253–8.
pubmed: 23358156
doi: 10.1038/mp.2012.184
Savage JE, Jansen PR, Stringer S, Watanabe K, Bryois J, de Leeuw CA, et al. Genome-wide association meta-analysis in 269,867 individuals identifies new genetic and functional links to intelligence. Nat Genet. 2018;50:912–9.
pubmed: 29942086
pmcid: 6411041
doi: 10.1038/s41588-018-0152-6
Genetics of Personality Consortium, de Moor MHM, van den Berg SM, KJH Verweij, Krueger RF, Luciano M, et al. Meta-analysis of genome-wide association studies for neuroticism, and the polygenic association with major depressive disorder. JAMA Psychiatry. 2015;72:642–50.
doi: 10.1001/jamapsychiatry.2015.0554
Hammerschlag AR, Stringer S, de Leeuw CA, Sniekers S, Taskesen E, Watanabe K, et al. Genome-wide association analysis of insomnia complaints identifies risk genes and genetic overlap with psychiatric and metabolic traits. Nat Genet. 2017;49:1584–92.
pubmed: 28604731
pmcid: 5600256
doi: 10.1038/ng.3888
The 23andMe Research Team, Jansen PR, Watanabe K, Stringer S, Skene N, Bryois J, et al. Genome-wide analysis of insomnia in 1,331,010 individuals identifies new risk loci and functional pathways. Nat Genet. 2019;51:394–403.
doi: 10.1038/s41588-018-0333-3
Stone MB. The FDA warning on antidepressants and suicidality — Why the controversy? N Engl J Med. 2014;371:1668–71. 30
pubmed: 25354102
doi: 10.1056/NEJMp1411138
Jaffe DH, Rive B, Denee TR. The humanistic and economic burden of treatment-resistant depression in Europe: a cross-sectional study. BMC Psychiatry. 2019;19:247. 07
pubmed: 31391065
pmcid: 6686569
doi: 10.1186/s12888-019-2222-4
Jakubovski E, Bloch MH. Prognostic subgroups for citalopram response in the STAR*D trial. J Clin Psychiatry. 2014;75:738–47.
pubmed: 24912106
pmcid: 4471174
doi: 10.4088/JCP.13m08727
Kubitz N, Mehra M, Potluri RC, Garg N, Cossrow N. Characterization of treatment resistant depression episodes in a cohort of patients from a US commercial claims database. PloS One. 2013;8:e76882.
pubmed: 24204694
pmcid: 3799999
doi: 10.1371/journal.pone.0076882
Blake H. Physical activity and exercise in the treatment of depression. Front Psychiatry. 2012;3:106.
pubmed: 23233842
pmcid: 3516810
doi: 10.3389/fpsyt.2012.00106
Murphy JA, Sarris J, Byrne GJ. A review of the conceptualisation and risk factors associated with treatment-resistant depression. Depress Res Treat. 2017;2017:4176825.
pubmed: 28840042
pmcid: 5559917
Cepeda MS, Reps J, Ryan P. Finding factors that predict treatment-resistant depression: results of a cohort study. Depress Anxiety. 2018;35:668–73.
pubmed: 29786922
pmcid: 6055726
doi: 10.1002/da.22774
Sternat T, Fotinos K, Fine A, Epstein I, Katzman MA. Low hedonic tone and attention-deficit hyperactivity disorder: risk factors for treatment resistance in depressed adults. Neuropsychiatr Dis Treat. 2018;14:2379–87.
pubmed: 30271154
pmcid: 6149933
doi: 10.2147/NDT.S170645
Ginsberg Y, Quintero J, Anand E, Casillas M, Upadhyaya HP. Underdiagnosis of attention-deficit/hyperactivity disorder in adult patients: a review of the literature. Prim Care Companion CNS Disord. 2014;16:PCC.13r01600.
MacQueen G, Santaguida P, Keshavarz H, Jaworska N, Levine M, Beyene J, et al. Systematic review of clinical practice guidelines for failed antidepressant treatment response in major depressive disorder, dysthymia, and subthreshold depression in adults. Can J Psychiatry. 2017;62:11–23.
pubmed: 27554483
doi: 10.1177/0706743716664885
Moran P, Rendu A, Jenkins R, Tylee A, Mann A. The impact of personality disorder in UK primary care: a 1-year follow-up of attenders. Psychol Med. 2001;31:1447–54.
pubmed: 11722159
doi: 10.1017/S003329170105450z
Visscher PM, Wray NR, Zhang Q, Sklar P, McCarthy MI, Brown MA, et al. 10 years of GWAS discovery: biology, function, and translation. Am J Hum Genet. 2017;101:5–22.
pubmed: 28686856
pmcid: 5501872
doi: 10.1016/j.ajhg.2017.06.005